A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Larazotide (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alba Therapeutics
  • Most Recent Events

    • 11 Sep 2017 The protocol has been amended to include efficacy as the primary endpoint along with the safety. The trial focus changes to TU and AR.
    • 12 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top